Similar results were obtained by testing other benzimidazole derivatives, such as flubendazole, which was able to target PD-1, but not PD-L1, in melanoma cells, and negatively affect tumor infiltration of MDSCs by inhibiting STAT3 phosphorylation [63]. The gene discussed is CD274; the disease is melanoma.